Effects of TENS in Pain During Application of Carboxytherapy in Patients With Gynoid Lipodystrophy

NCT ID: NCT02743403

Last Updated: 2017-05-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-01-31
• Study Completion Date: 2016-06-30

Brief Summary

The project aims to compare the use of carboxiterapia ( therapeutic administration of carbon dioxide) with the use of active TENS and placebo TENS using the VAS scale as a parameter. The therapy used was started in the 30s , with carbonated water baths, and , lately, is involved in the therapeutic arsenal of numerous diseases , Both for treatment of diseases when for aesthetic treatments , especially for the gynoid lipodystrophy. However, the therapy presents CO2 in clinical practice, limiting factors for its use , such as pain at the injection site , small bruises or welts due to several punctures and feeling of crepitus. To try to combat these " side effects " that can last up to 30 minutes, the TENS was used in order to determine whether the use of this electric current helps at improvement of discomfort.

Detailed Description

The assessment and intervention will be carried out only by the researcher, which has physical therapy training and expertise in dermato-functional physiotherapy with clinical experience in 11 years, as well as fulfilling all the prerequisites required for the management of carboxytherapy, according the judgment 293 of 16 June 2012 the Federal Council of Physical Therapy and Occupational Therapy (COFFITO). Patients will be submitted for assessment and intervention once.

Assessments should contain demographic information of the participants by asking questions such as age, marital status, education and contact, lifestyle, gynecological history, surgical history, anthropometric measurements and physical inspection examination (Annex 3). Patients are advised not to make use of any medication for pain relief such as painkillers and anti-inflammatories, within 4 hours before the physiotherapy session. For physical examination, evaluations will be conducted in the standing position, with bathing suit, keeping the gluteal region with maximum visibility. The appraiser will inspect the bilateral gluteal region, to confirm the moderate degree of severity of the gynoid lipodystrophy, defined by the gynoid lipodystrophy severity scale, with the number of skin depressions (ND) in moderate amount, ND≥ 5-9 depressions, according CSS classification.

For the study, three groups will be divided: group A (active TENS + active Carboxytherapy), Y group (TENS placebo + active Carboxytherapy) and S (active - control Carboxytherapy). Group A (active TENS + active Carboxytherapy) will be submitted to the application of TENS during the application of Carboxytherapy, both linked. The Y group (TENS placebo + active Carboxytherapy) will be submitted to the application of Carboxytherapy and TENS with low-dose therapy. The group S (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS. Prior to the beginning of the study, both devices will be calibrated. The gluteal that receive the intervention will be defined by lot.

After drawing the group and laterality of the gluteal region that receive the intervention, will be marked by white pencil, the depressions of the skin with cellulite and the delimitation of the area, from the following lines: lateral line will have as midpoint the greater trochanter, where a vertical line will be drawn from the iliac crest to the lateral edge of the gluteal groove; top line will be drawn a horizontal line parallel to the gluteal groove, 4 cm below the posterior superior iliac spine to the vertical line drawn previously from the greater trochanter bottom line will be drawn a horizontal line delimiting the gluteal groove; the medial end of the gluteal groove to the vertical line drawn previously from the greater trochanter; medial line is delimited by anatomically intergluteal slot.

Conditions

Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neurodyn Portable TENS

Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.

The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.

The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.

Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.

Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject.

Group Type: ACTIVE_COMPARATOR

Neurodyn Portable activeTENS, IBRAMED®

Intervention Type: DEVICE

Randomization and secret Allocation active TENS (GI / n = 27)

Neurodyn Portable placeboTENS, IBRAMED®

Intervention Type: DEVICE

Randomization and secret Allocation placebo TENS (GII / n = 27)

Carboxyderm S20-1C

Intervention Type: DEVICE

Randomization and secret Allocation control group (CG / n = 27).

Placebo TENS- Neurodyn Portable TENS

Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.

The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active.

Group Type: PLACEBO_COMPARATOR

Neurodyn Portable activeTENS, IBRAMED®

Intervention Type: DEVICE

Randomization and secret Allocation active TENS (GI / n = 27)

Neurodyn Portable placeboTENS, IBRAMED®

Intervention Type: DEVICE

Randomization and secret Allocation placebo TENS (GII / n = 27)

Carboxyderm S20-1C

Intervention Type: DEVICE

Randomization and secret Allocation control group (CG / n = 27).

Control

Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.

The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Neurodyn Portable activeTENS, IBRAMED®

Randomization and secret Allocation active TENS (GI / n = 27)

Intervention Type: DEVICE

Neurodyn Portable placeboTENS, IBRAMED®

Randomization and secret Allocation placebo TENS (GII / n = 27)

Intervention Type: DEVICE

Carboxyderm S20-1C

Randomization and secret Allocation control group (CG / n = 27).

Intervention Type: DEVICE

Other Intervention Names

Carboxyderm S20-1C; Carboxyderm S20-1C

Eligibility Criteria

Inclusion Criteria

• Body mass index < 18,5 a 29,9 kg/m²
• with regular menstrual cycle
• without prior experience with carboxytherapy and TENS
• with the presence of moderate gynoid lipodystrophy at gluteal region as classification Hexsel Dal'Forno & Hexsel (CSS )

Exclusion Criteria

• pregnant women;
• nursing mothers;
• women with metabolic disorders and autoimmune diseases;
• which are suffering from skin lesions in the gluteal region and who have undergone surgical procedures in gluteus;
• the presence of malignant or benign tumor;
• with metal or silicone implants;
• heart disease and / or use of pacemakers, hypoesthesia or anesthesia in the gluteal region;
• women who have the risk of presenting epilepsy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 44 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Universidade Cidade de Sao Paulo

OTHER

Sponsor Role: lead

Responsible Party

Adria Yared Sadala

Clinical Researcher

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Richard E Liebano, PhD

Role: STUDY_DIRECTOR

Locations

Universidade Cidade de São Paulo

São Paulo, , Brazil

Countries

Brazil

Other Identifiers

Carboxytherapy,TENS and pain

Identifier Type: -

Identifier Source: org_study_id